Business
Norgine enhances hepatology and specialty portfolio through exclusive in-licensing agreement with Vir Biotechnology
Norgine, a leading European specialty pharmaceutical company, today announced an exclusive licensing agreement under which Norgine will commercialise the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta (CHD) in Europe, Australia and New Zealand following the necessary marketing authorisations. There is a high unmet medical need for effective treatments for CHD given potential limitations with existing treatment options.
About this update from Vir Biotechnology, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Agreement underscores Norgine's mission to bring innovative therapies to patients and builds on our heritage in hepatology and specialty pharmaceuticals.","length":157,"tagName":"p"}]},{"val":[{"type":"text","content":"Vir Biotechnology's chronic hepatitis delta treatment candidate has shown robust virological responses and reflects a differentiated approach to treatment.","length":159,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":316,"olType":false},{"type":"text","content":"UXBRIDGE, England, Dec. 17, 2025 /PRNewswire/ -- Norgine, a leading European specialty pharmaceutical company, today announced an exclusive licensing agreement under which Norgine will commercialise the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta (CHD) in Europe, Australia and New Zealand following the necessary marketing authorisations. There is a high unmet medical need for effective treatments for CHD given potential limitations with existing treatment options. ","length":524,"tagName":"p"},{"type":"image","alt":"Norgine Logo (PRNewsfoto/Norgine Pharmaceuticals Limited)","displaySize":"","headline":null,"caption":"Norgine Logo (PRNewsfoto/Norgine Pharmaceuticals Limited)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":302,"url":"https://media.zenfs.com/en/prnewswire.com/cd939183b6213b3bca59c87dfdaf20df"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ey6eXsxpzA7ioTLr9hq.sQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTUzMjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/cd939183b6213b3bca59c87dfdaf20df","width":400,"height":302}},"href":"https://mma.prnewswire.com/media/2846726/5684424/Norgine_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Under the terms of the licensing agreement, Vir Biotechnology will receive a EUR 55 million initial reimbursement payment and up to EUR 495 million in potential regulatory and commercial milestone payments. Additionally, Vir Biotechnology will receive tiered, mid-teen to high-twenties percent royalties on net sales in Norgine's licensed territories. Clinical development costs for the ongoing trials in Vir Biotechnology's ECLIPSE registrational program (ECLIPSE 1, 2 and 3) will be shared, with Norgine contributing ...